Please use this identifier to cite or link to this item:
Title: Development of HIV-1 fusion inhibitors targeting gp41
Authors: Lu, K.
Asyifah, M. R.
Shao, F.
Zhang, D.
Keywords: DRNTU::Science::Medicine::Biomedical engineering
Issue Date: 2014
Source: Lu, K., Asyifah, M., Shao, F., & Zhang, D. (2014). Development of HIV-1 Fusion Inhibitors Targeting gp41. Current Medicinal Chemistry, 21(17), 1976-1996.
Series/Report no.: Current medicinal chemistry
Abstract: The HIV-1 envelope protein glycoprotein 41 (gp41) is crucial in the HIV-1 infection process, therefore gp41 has emerged as an attractive target for drug design against AIDS. During the past few decades, tremendous efforts have been made on developing inhibitors that can prevent the HIV-1 entry process via suppressing functional gp41. In this review, the development of HIV-1 fusion inhibitors targeting gp41 including peptide inhibitors, small molecule inhibitors, vaccines and neutralized antibodies will be discussed.
ISSN: 0929-8673
DOI: 10.2174/0929867321666131218094559
Rights: © 2014 Bentham Science Publishers.
Fulltext Permission: none
Fulltext Availability: No Fulltext
Appears in Collections:SPMS Journal Articles

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.